Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $95.00 at DA Davidson

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its price target lifted by equities researchers at DA Davidson from $93.00 to $95.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. DA Davidson's target price would suggest a potential upside of 28.90% from the stock's previous close.

Several other brokerages also recently commented on PBH. Canaccord Genuity Group reissued a "buy" rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. StockNews.com cut shares of Prestige Consumer Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.75.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded up $1.09 during trading on Wednesday, hitting $73.70. 185,335 shares of the company's stock traded hands, compared to its average volume of 249,339. The stock has a market capitalization of $3.66 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 1.94 and a beta of 0.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The business has a 50 day moving average of $69.43 and a 200-day moving average of $69.14. Prestige Consumer Healthcare has a 12-month low of $56.34 and a 12-month high of $75.31.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare's revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.06 EPS. As a group, equities research analysts anticipate that Prestige Consumer Healthcare will post 4.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $25,000. Opal Wealth Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare in the second quarter worth $26,000. Principal Securities Inc. bought a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $29,000. Quest Partners LLC grew its holdings in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company's stock worth $30,000 after acquiring an additional 424 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock valued at $33,000 after acquiring an additional 208 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.